BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FDA-Approved Telescope Implant Restores Sight to Those With Macular Degeneration, Ophthalmology, American Journal of Ophthalmology, and Archives of Ophthalmology


1/8/2013 8:55:56 AM

WILMINGTON, N.C., Jan. 7, 2013 /PRNewswire/ -- Imagine the heartbreak for someone who gradually loses the ability to see her grandchildren, husband and the people who mean the most to her. Now imagine her joy when she can see them again. Thanks to a groundbreaking new treatment program called CentraSight, this dream can now be a reality for patients around the country with end-stage age related macular degeneration (AMD), the leading cause of blindness in older Americans.

Smaller than a pea, the telescope is implanted in one eye in an outpatient surgical procedure. In the implanted eye, the device renders enlarged central vision images over a wide area of the retina to improve central vision, while the non-operated eye provides peripheral vision for mobility and orientation.

"Patients living with end-stage macular degeneration have extreme difficulty performing simple, everyday tasks. Both eyes have central visual loss, so recognizing faces of friends and family, performing activities of daily living, and safely crossing the street becomes impossible. This can have a debilitating effect, both physically and psychologically," said Edward Paul, O.D., Ph.D., a low vision specialist and CentraSight team leader for North Carolina. "For many, this device has made a marked improvement in their lives," said Dr. Paul. "We are very encouraged that Medicare has granted access for this new treatment option to eligible patients in the State of North Carolina."

Results from the two U.S. clinical trials, conducted at 28 leading ophthalmic centers, have been published in peer-reviewed scientific journals including Ophthalmology, American Journal of Ophthalmology, and Archives of Ophthalmology. Most recently, in the September 2011 issue of Ophthalmology, a study reports the intraocular telescope improves quality of life and is cost effective.

For patients ineligible for the implanted telescope, an external telescope in the same power can be mounted in special eyeglasses.

Patients and physicians can find more information about the telescope implant and related treatment program at www.DrEdwardPaul.com or by calling 1-866-366-2040.

Press Release Contact Information:

Edward Paul, O.D. Ph.D.
CentraSight Low Vision Specialist
www.DrEdwardPaul.com
(866) 366-2040
epauljr@aol.com

This release was issued through WebWire(R). For more information visit http://www.webwire.com.

SOURCE www.DrEdwardPaul.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES